SI2364729T1 - IL-17 antagonistična protitelesa - Google Patents

IL-17 antagonistična protitelesa

Info

Publication number
SI2364729T1
SI2364729T1 SI200531869T SI200531869T SI2364729T1 SI 2364729 T1 SI2364729 T1 SI 2364729T1 SI 200531869 T SI200531869 T SI 200531869T SI 200531869 T SI200531869 T SI 200531869T SI 2364729 T1 SI2364729 T1 SI 2364729T1
Authority
SI
Slovenia
Prior art keywords
antagonistic antibodies
antagonistic
antibodies
Prior art date
Application number
SI200531869T
Other languages
English (en)
Slovenian (sl)
Inventor
Padova Franco E. Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2364729(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2364729T1 publication Critical patent/SI2364729T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200531869T 2004-08-05 2005-08-04 IL-17 antagonistična protitelesa SI2364729T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
EP10175150.1A EP2364729B3 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Publications (1)

Publication Number Publication Date
SI2364729T1 true SI2364729T1 (sl) 2014-08-29

Family

ID=32982602

Family Applications (4)

Application Number Title Priority Date Filing Date
SI200531390T SI1776142T1 (sl) 2004-08-05 2005-08-04 Antagonistična protitelesa proti IL-17
SI200532208T SI2902039T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies
SI200531869T SI2364729T1 (sl) 2004-08-05 2005-08-04 IL-17 antagonistična protitelesa
SI200531965T SI2366405T1 (sl) 2004-08-05 2005-08-04 IL-17antagonistična protitelesa

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200531390T SI1776142T1 (sl) 2004-08-05 2005-08-04 Antagonistična protitelesa proti IL-17
SI200532208T SI2902039T1 (en) 2004-08-05 2005-08-04 IL-17 antagonistic antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200531965T SI2366405T1 (sl) 2004-08-05 2005-08-04 IL-17antagonistična protitelesa

Country Status (40)

Country Link
US (9) US7807155B2 (enExample)
EP (5) EP2902039B1 (enExample)
JP (1) JP4682200B2 (enExample)
KR (2) KR20080029018A (enExample)
CN (1) CN101001645B (enExample)
AR (1) AR050200A1 (enExample)
AT (1) ATE517924T1 (enExample)
AU (2) AU2005268857C1 (enExample)
BE (1) BE2015C041I2 (enExample)
BR (3) BR122018075556B1 (enExample)
CA (1) CA2573586C (enExample)
CY (6) CY1111963T1 (enExample)
DK (4) DK2902039T3 (enExample)
EC (1) ECSP077198A (enExample)
ES (4) ES2677245T3 (enExample)
FR (1) FR15C0048I2 (enExample)
GB (1) GB0417487D0 (enExample)
HK (1) HK1256639A1 (enExample)
HR (3) HRP20110758T4 (enExample)
HU (4) HUE025815T2 (enExample)
IL (1) IL180717A (enExample)
LT (3) LT2902039T (enExample)
LU (2) LU92768I2 (enExample)
MA (1) MA28982B1 (enExample)
MX (1) MX2007001338A (enExample)
MY (1) MY144925A (enExample)
NL (1) NL300749I2 (enExample)
NO (9) NO336279B1 (enExample)
NZ (1) NZ552658A (enExample)
PE (1) PE20060418A1 (enExample)
PL (4) PL2366405T3 (enExample)
PT (4) PT2366405E (enExample)
RU (2) RU2426741C3 (enExample)
SG (1) SG155186A1 (enExample)
SI (4) SI1776142T1 (enExample)
TN (1) TNSN07034A1 (enExample)
TR (1) TR201808057T4 (enExample)
TW (1) TWI359153B (enExample)
WO (1) WO2006013107A1 (enExample)
ZA (1) ZA200700242B (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
CN101326195B9 (zh) * 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
SI2532681T1 (sl) 2005-12-20 2015-03-31 Sbi Biotech Co., Ltd. Protitelo proti-ILT7
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
AU2007235199B8 (en) * 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
BRPI0715917A2 (pt) * 2006-08-11 2014-11-25 Schering Corp Anticorpos para il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
NZ579297A (en) 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
KR102824865B1 (ko) 2007-05-29 2025-06-26 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2242504B1 (en) 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
EP2279001B1 (en) * 2008-04-29 2015-09-30 Amgen Research (Munich) GmbH Inhibitors of gm-csf and il-17 for therapy
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
BRPI0919531A2 (pt) * 2008-09-29 2015-12-08 Roche Glycart Ag anticorpos contra il17 humana e usos dos mesmos
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
EP3275900A1 (en) * 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2493506B1 (en) 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a antagonists
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
EP2601218A4 (en) 2010-08-03 2015-02-18 Abbvie Inc VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
JP2013537414A (ja) * 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Ｉｌ−１７に対する抗体
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
WO2012045848A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
KR20180129991A (ko) * 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
PT2663577T (pt) 2011-01-14 2017-07-19 Ucb Biopharma Sprl Anticorpo de ligação a il-17a e il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
WO2012135415A1 (en) * 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
KR20140097178A (ko) 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
KR20150010709A (ko) 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2636043C2 (ru) 2012-11-01 2017-11-17 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
TWI632159B (zh) 2013-02-08 2018-08-11 諾華公司 抗－ｉｌ－１７ａ抗體及其於治療自體免疫及發炎病症之用途
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
EP3072905B1 (en) * 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
SI3191120T1 (sl) 2014-09-10 2024-10-30 Novartis Ag Uporaba antagonistov IL-17 za zaviranje napredovanja strukturne poškodbe pri pacientih s psoriatičnim artritisom
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN108064235A (zh) 2015-01-12 2018-05-22 阿菲博迪公司 Il-17a结合多肽
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016294332A1 (en) 2015-07-16 2017-11-30 Eli Lilly And Company Treatment of pruritus
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
IL297775A (en) 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
EP3426680B1 (en) 2016-03-10 2024-08-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
JP2019521156A (ja) 2016-07-19 2019-07-25 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
WO2018050028A1 (zh) 2016-09-14 2018-03-22 北京韩美药品有限公司 一种能够特异性地结合il-17a的抗体及其功能片段
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
RU2020117362A (ru) 2017-11-02 2021-12-02 Новартис Аг Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17)
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
US20210079087A1 (en) * 2018-03-29 2021-03-18 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
CN112513078B (zh) * 2018-07-31 2022-11-18 沈为群 抗il-17a抗体及其用途
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
WO2020243504A1 (en) * 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CN114286827B (zh) 2019-07-26 2024-01-12 神州细胞工程有限公司 人源化抗il17a抗体及其应用
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
CN114981302A (zh) 2019-09-20 2022-08-30 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法
JP7093940B2 (ja) * 2019-09-25 2022-07-01 国立大学法人 東京大学 全身性強皮症治療用医薬組成物
CN114729943B (zh) 2019-09-30 2025-07-22 詹森药业有限公司 用大分子调节剂进行il-17靶接合测定的组合物和方法
CA3161801A1 (en) 2019-11-19 2021-05-27 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
IL293354A (en) 2019-12-06 2022-07-01 Novartis Ag Methods of treating lichen planus using interleukin-17 (il-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
EP4168117A1 (en) 2020-06-23 2023-04-26 Novartis AG Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
WO2022117773A1 (en) 2020-12-02 2022-06-09 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
JP2023554489A (ja) 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
US20250276957A1 (en) 2022-04-25 2025-09-04 Novartis Ag Crystalline forms of an il-17 inhibitor
CA3253618A1 (en) 2022-05-16 2023-11-23 Novartis Ag METHODS FOR TREATMENT OF GIANT CELL ARTERITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
EP4525914A1 (en) 2022-05-18 2025-03-26 Novartis AG Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
EP4654999A1 (en) 2023-01-27 2025-12-03 Fresenius Kabi Deutschland GmbH Biopharmaceutical composition
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
GB202407664D0 (en) 2024-05-30 2024-07-17 Fresenius Kabi Deutschland Gmbh Post-translational control of recombiant proteins
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
MX9707021A (es) 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
CA2227220A1 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
DE69623316T2 (de) 1995-10-27 2003-04-17 Institut National De La Sante Et De La Recherche Medicale I.N.S.E.R.M., Paris Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ES2326347T3 (es) 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
DE69841140D1 (de) 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
AU760035B2 (en) 1997-11-10 2003-05-08 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
JP2003502006A (ja) 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
MXPA00007889A (es) 1998-02-11 2002-09-18 Maxygen Inc Optimizacion de las propiedades inmunomoduladoras de las vacunas geneticas.
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
WO2000015798A2 (en) 1998-09-17 2000-03-23 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9 (ztgfss9)
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
ATE444365T1 (de) 1999-01-11 2009-10-15 Schering Corp Interleukin-17 verwandte zytokine aus säugetieren. dafür kodierende polynukleotide. verwendungen
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
US7115261B1 (en) 1999-02-12 2006-10-03 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
DK1294769T3 (da) 2000-06-16 2011-04-26 Human Genome Sciences Inc Antistoffer der immunspecifikt binder til BLyS
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001296229A1 (en) 2000-10-13 2002-04-29 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
WO2002058717A2 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
EP2366406A1 (en) 2001-01-25 2011-09-21 ZymoGenetics, Inc. Method for treating psoriasis
ATE374214T1 (de) * 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
AU2002364954A1 (en) 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
CA2526398C (en) * 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2007027761A2 (en) 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
SI1776142T1 (sl) 2011-11-30
US20100215666A1 (en) 2010-08-26
IL180717A0 (en) 2007-06-03
TNSN07034A1 (en) 2008-06-02
MA28982B1 (fr) 2007-11-01
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
KR100852523B9 (ko) 2025-03-28
LT2902039T (lt) 2018-06-25
PL2366405T3 (pl) 2015-08-31
US20090280131A1 (en) 2009-11-12
RU2011113153A (ru) 2012-10-20
US7807155B2 (en) 2010-10-05
LUC00088I2 (enExample) 2018-12-17
RU2426741C3 (ru) 2017-11-15
PT2364729E (pt) 2014-09-01
NO337129B1 (no) 2016-01-25
AU2010201689A1 (en) 2010-05-20
PT2902039T (pt) 2018-07-17
MX2007001338A (es) 2008-03-11
CY1120723T1 (el) 2019-12-11
JP4682200B2 (ja) 2011-05-11
HRP20181069T1 (hr) 2018-09-07
CA2573586C (en) 2013-06-25
US20190270804A1 (en) 2019-09-05
HK1256639A1 (en) 2019-09-27
ATE517924T1 (de) 2011-08-15
NO341384B1 (no) 2017-10-30
ES2487533T3 (es) 2014-08-21
EP1776142B1 (en) 2011-07-27
PL1776142T3 (pl) 2011-12-30
EP2366405A3 (en) 2012-01-18
HK1101277A1 (en) 2007-10-12
PL2364729T6 (pl) 2016-06-30
EP2364729A3 (en) 2012-01-18
CY2018027I1 (el) 2020-05-29
BRPI0513078B8 (pt) 2019-08-27
US8617552B2 (en) 2013-12-31
EP2364729B3 (en) 2015-06-24
SG155186A1 (en) 2009-09-30
ZA200700242B (en) 2008-08-27
HK1207559A1 (en) 2016-02-05
EP2364729A2 (en) 2011-09-14
PT2366405E (pt) 2015-06-30
KR100852523B1 (ko) 2008-08-14
SI2902039T1 (en) 2018-07-31
BRPI0513078C1 (pt) 2021-05-25
DK2366405T3 (en) 2015-05-11
KR20080029018A (ko) 2008-04-02
NO2015023I1 (no) 2015-11-02
NO337286B1 (no) 2016-02-29
CA2573586A1 (en) 2006-02-09
HRP20110758T4 (hr) 2015-07-31
HUS1800040I1 (hu) 2018-11-28
PL1776142T6 (pl) 2016-06-30
SI2366405T1 (sl) 2015-07-31
LTC1776142I2 (lt) 2022-07-11
JP2008507988A (ja) 2008-03-21
ES2487533T7 (es) 2015-07-14
EP2366405B1 (en) 2015-02-25
DK2902039T3 (en) 2018-07-16
EP2902039B1 (en) 2018-04-11
CN101001645B (zh) 2012-09-05
DK2364729T6 (en) 2015-07-06
ES2536228T3 (es) 2015-05-21
ES2367440T7 (es) 2015-07-14
AR050200A1 (es) 2006-10-04
TR201808057T4 (tr) 2018-06-21
PL2902039T3 (pl) 2018-09-28
AU2010201689B2 (en) 2011-09-29
PE20060418A1 (es) 2006-06-15
WO2006013107A1 (en) 2006-02-09
PL2364729T3 (pl) 2014-10-31
AU2005268857B2 (en) 2010-01-28
HRP20110758T1 (en) 2011-11-30
EP1776142B3 (en) 2015-06-24
ES2367440T3 (es) 2011-11-03
ES2367440T9 (es) 2021-04-28
US20120107325A1 (en) 2012-05-03
CY1115444T1 (el) 2017-01-04
HUE038187T2 (hu) 2018-10-29
FR15C0048I1 (fr) 2015-08-28
KR20070036166A (ko) 2007-04-02
US20230235038A1 (en) 2023-07-27
US8119131B2 (en) 2012-02-21
NO20070985L (no) 2007-03-30
NO348010B1 (no) 2024-06-17
TWI359153B (en) 2012-03-01
GB0417487D0 (en) 2004-09-08
NO2015023I2 (no) 2015-10-26
CY2018027I2 (el) 2020-05-29
NZ552658A (en) 2009-11-27
CN101001645A (zh) 2007-07-18
BRPI0513078B1 (pt) 2019-02-19
HUE025815T2 (en) 2016-04-28
MY144925A (en) 2011-11-30
NO20171697A1 (no) 2007-03-30
LTPA2018515I1 (lt) 2018-10-25
EP2902039A1 (en) 2015-08-05
HUS1500037I1 (hu) 2017-10-30
DK1776142T6 (en) 2015-07-06
CY2015030I1 (el) 2015-11-04
IL180717A (en) 2012-07-31
NO20151787L (no) 2006-02-06
NO336279B1 (no) 2015-07-06
FR15C0048I2 (fr) 2015-11-20
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
BR122018075556B1 (pt) 2022-10-18
NL300749I2 (nl) 2017-11-02
AU2005268857A1 (en) 2006-02-09
EP2364729B1 (en) 2014-05-14
CY1111963T1 (el) 2015-11-04
TW200617025A (en) 2006-06-01
LTPA2015029I1 (lt) 2022-07-11
PT1776142E (pt) 2011-10-06
EP1776142A1 (en) 2007-04-25
DK1776142T3 (da) 2011-10-31
HRP20150480T1 (hr) 2015-07-17
US20170355762A1 (en) 2017-12-14
US10344084B2 (en) 2019-07-09
CY2015030I2 (el) 2017-11-14
RU2426741C2 (ru) 2011-08-20
NO20150065L (no) 2007-03-30
DK2364729T3 (da) 2014-07-21
BRPI0513078A (pt) 2008-04-22
BE2015C041I2 (enExample) 2024-10-08
LU92768I2 (fr) 2015-11-03
NO2018007I1 (no) 2018-02-14
US20140079719A1 (en) 2014-03-20
US20250122277A1 (en) 2025-04-17
ECSP077198A (es) 2007-02-28
AU2005268857C1 (en) 2012-01-19
AU2005268857B8 (en) 2010-05-27
EP3409288A1 (en) 2018-12-05
CY1116256T1 (el) 2017-02-08
EP1776142B9 (en) 2016-09-07
ES2677245T3 (es) 2018-07-31
BR122017009404B1 (pt) 2022-02-22
NO20150064L (no) 2007-03-30
PL1776142T4 (pl) 2018-04-30
NO2016017I1 (no) 2016-08-23
EP2366405A2 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
HUS1800040I1 (hu) IL-17 antagonista antitestek
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
IL237756A0 (en) Antibody compositions
IL179672A0 (en) Anti-cd3 antibodies
IL197158A0 (en) Antagonistic human light-specific human monoclonal antibodies
IL182554A0 (en) Anti-addl antibodies and uses thereof
GB0420466D0 (en) Anti-glucan antibodies
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
ZA200701952B (en) Anti-OX40L antibodies
GB0413257D0 (en) Backpack
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0418415D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0413446D0 (en) Spot-on